US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
NL296693A
(da)
*
|
1962-08-16 |
|
|
|
FR95908E
(fr)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants.
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
DE2902172C2
(de)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins
|
WO1983003755A1
(en)
*
|
1982-04-23 |
1983-11-10 |
Caola Kozmetikai És Háztartäsvegyipari Vállalat |
Novel cosmetic compositions containing prenylamine and a process for their preparation
|
NZ215753A
(en)
*
|
1985-04-16 |
1989-10-27 |
Hoffmann La Roche |
Phenethanolamine derivatives and pharmaceutical compositions
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
HUP0303917A2
(hu)
*
|
2001-01-26 |
2004-03-01 |
Schering Corporation |
Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
|
PE20020850A1
(es)
*
|
2001-01-26 |
2002-09-21 |
Schering Corp |
Utilizacion de compuestos de azetidinona sustituida para tratamiento de la sitosterolemia
|
ES2286233T3
(es)
*
|
2001-01-26 |
2007-12-01 |
Schering Corporation |
Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares.
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
SK287988B6
(sk)
*
|
2001-01-26 |
2012-09-03 |
Schering Corporation |
Composition, oral dosage form and use thereof
|
EP1671650A1
(en)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
AR035739A1
(es)
*
|
2001-01-26 |
2004-07-07 |
Schering Corp |
Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
|
JP2004532868A
(ja)
*
|
2001-05-25 |
2004-10-28 |
シェーリング コーポレイション |
アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
|
MXPA04002573A
(es)
*
|
2001-09-21 |
2004-06-18 |
Schering Corp |
Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
JP4395370B2
(ja)
*
|
2001-09-21 |
2010-01-06 |
シェーリング コーポレイション |
ステロール吸収阻害剤を使用して血管炎症を治療または予防する方法
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
ES2362998T3
(es)
|
2002-08-19 |
2011-07-18 |
Pfizer Inc. |
Terapia de combinación para enfermedades hiperproliferativas.
|
WO2004043457A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
US7192944B2
(en)
*
|
2003-03-07 |
2007-03-20 |
Schering Corp. |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ATE406364T1
(de)
|
2003-03-07 |
2008-09-15 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
JP4589919B2
(ja)
|
2003-03-07 |
2010-12-01 |
シェーリング コーポレイション |
高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
CA2544309A1
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US20060147520A1
(en)
*
|
2004-07-26 |
2006-07-06 |
Curtis Ruegg |
Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
EP2351569B1
(en)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
EP2111863B1
(en)
|
2005-10-26 |
2012-03-28 |
Asahi Kasei Pharma Corporation |
Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012037665A1
(en)
|
2010-09-24 |
2012-03-29 |
Oral Delivery Technology Ltd. |
Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
AU2014255381A1
(en)
|
2013-04-17 |
2015-10-08 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
MX2021008533A
(es)
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|